Receptor News and Research

RSS

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

The ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 190 million cases worldwide. Of these, over 4 million have died due to the infection.

20 Jul 2021

Exhausted T cells linked to increased risk of COVID-19 mortality

New research led by Nadia R. Roan of Gladstone Institutes and the University of California, San Francisco, finds a correlation between high numbers of inflammatory CXCR4+ T cells and regulatory T cells specific to SARS-CoV-2 and dying from infection. In contrast, people who recovered from severe COVID-19 illness were more likely to have many SARS-CoV-2-specific T cells that perform homeostatic proliferation.

20 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

A new study evaluates the efficacy of vaccine- and infection-induced antibodies against SARS-CoV-2 variants.

19 Jul 2021

Novel coronavirus found in UK horseshoe bats

A coronavirus related to the virus that causes Covid-19 in humans has been found in UK horseshoe bats - according to new collaborative research from the University of East Anglia, ZSL (Zoological Society of London), and Public Health England (PHE).

19 Jul 2021

Study reveals pathological mechanism and treatment strategy of pre-engraftment syndrome

The research team led by Prof. WEI Haiming and Prof. TIAN Zhigang from Division of Life Sciences and Medicine, University of Science and Technology of China of the Chinese Academy of Sciences, collaborating with the research group led by Prof. SUN Zimin from the First Affiliated Hospital of USTC revealed the pathological mechanism of severe pre-engraftment syndrome (PES) after umbilical cord blood transplantation, not only providing a treatment strategy for patients with PES, but significantly guiding for further improvement in the curative effect of unrelated cord blood transplantation (UCBT).

19 Jul 2021

Do mRNA-based COVID-19 vaccines induce memory T cell response similar to natural infection?

A team of scientists from the United States has recently compared the epitope-specific T cell response after natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination in both naïve and previously infected individuals.

19 Jul 2021

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

A new study has been published on the bioRxiv* preprint server, which focuses on the mechanism behind the binding of SARS-CoV-2 with the host receptor, using a molecular dynamics approach. The authors of this study aim to highlight the role of glycans in initiating the interaction between S and ACE2.

19 Jul 2021

Researchers conduct molecular dynamic study of SARS-CoV-2 spike glycoprotein and human skin model interactions

Currently, there is a lack of understanding of the physico-chemical features of the interaction between coronaviruses and different surfaces. However, new research has been published on the bioRxiv* preprint server that documents the molecular details of the interaction between the human skin and SARS-CoV-2.

19 Jul 2021

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies.

19 Jul 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

How do immunocompromised patients respond to COVID-19 vaccines?

The COVID-19 vaccines produce a boost in antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, new research suggests vaccine responses aren’t all created equal. Their findings showed that immunocompromised patients, such as transplant recipients, with no prior exposure to SARS-CoV-2 produce little to no neutralizing antibodies.

18 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

Sophisticated stem cell model reveals potential route of SARS-CoV-2 entry into the brain

Researchers at University of California San Diego School of Medicine and Rady Children's Institute for Genomic Medicine have produced a stem cell model that demonstrates a potential route of entry of SARS-CoV-2, the virus that causes COVID-19, into the human brain.

16 Jul 2021

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.

16 Jul 2021

Mixing COVID vaccines generates a comparable immune response

The validity and safety of mixing first and second doses of different types are explored in a paper recently uploaded to the preprint server medRxiv* by Rose et al. (July 13th, 2021), finding that robust antibody response is induced, comparable to, and perhaps even exceed that generated by homologous dosing.

16 Jul 2021

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Researchers in the United States have designed a modular protein subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited a strong immune response in macaques and prevented the animals from developing coronavirus disease 2019 (COVID-19).

15 Jul 2021

Potential compounds targeting SARS-COV-2 main protease (in vivo)

Now, new research published in the journal Hippokratia focuses on assisting the ongoing COVID-19 therapeutic research by developing a new method to identify active compounds that have the potential to fight against COVID-19 infection.

15 Jul 2021

Short chain fatty acids have potential therapeutic applications against COVID-19, study suggests

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is highly transmissible, with nasal passages being the target of original infection.

15 Jul 2021

Receptor News and Research

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

Exhausted T cells linked to increased risk of COVID-19 mortality

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

Novel coronavirus found in UK horseshoe bats

Study reveals pathological mechanism and treatment strategy of pre-engraftment syndrome

Do mRNA-based COVID-19 vaccines induce memory T cell response similar to natural infection?

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

Researchers conduct molecular dynamic study of SARS-CoV-2 spike glycoprotein and human skin model interactions

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

How do immunocompromised patients respond to COVID-19 vaccines?

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

Sophisticated stem cell model reveals potential route of SARS-CoV-2 entry into the brain

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

Mixing COVID vaccines generates a comparable immune response

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Potential compounds targeting SARS-COV-2 main protease (in vivo)

Short chain fatty acids have potential therapeutic applications against COVID-19, study suggests

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News